|
Greetings!
On WEDNESDAY, NOVEMBER 17, 2010, THE SCLERODERMA FOUNDATION IS ASKING ITS MEMBERS TO CALL THEIR U.S. SENATORS and urge them to support H.R. 2408 as passed by the House of Representatives.
On September 30th, the House of Representatives passed the Scleroderma Research and Awareness Act (H.R. 2408) by a voice vote before entering a period of recess to prepare for the November 2nd elections. This is a huge milestone for scleroderma patients everywhere!
In order for the Scleroderma Research and Awareness Act to become law, the United States Senate must pass the House-passed version of this important legislation. Congress is currently out of session until mid-November, after the elections they will return for a limited time between mid-November and early-mid December. This is our opportunity to see a bill become a law on scleroderma and we need you to reach out to your Senators (2 from each state) and ask them to pass H.R. 2408 so it can be signed into law by the president.
To learn how to best contact your Senators, please click here or visit our Web site Advocacy page by clicking on the Quick Links! |
Systemic Sclerosis - A Bird's Eye Review of the Recent Literature |
Click here to read this article in the Clinical and Experimental Rheumatology Journal. |
|
Family Health History Resources |
The Genetic Alliance Web site offers comprehensive resources about the importance and gathering of family health history.
To view more information please click here. |
| Influence of Childhood Scleroderma on Physical Function and Quality of Life - An Abstract |
Abstract Objective - There have been few studies of quality of life in childhood scleroderma and these focused predominantly on self-perception and the influence of skin lesions. This cross-sectional study aimed to describe the influence of childhood scleroderma on physical function and quality of life in relation to clinical and demographic measures. |
|
Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial |
Potential Therapy for Lung Fibrosis in Scleroderma and Idiopathic Pulmonary Fibrosis
SAN DIEGO, Oct. 28 /PRNewswire -- Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects. For more information on this clinical trial, please click here. 
|
